# Extension Study of Participants From SPG302-ALZ-101

> **NCT06833281** · PHASE2 · TERMINATED · sponsor: **Spinogenix** · enrollment: 12 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SPG302

## Key facts

- **NCT ID:** NCT06833281
- **Lead sponsor:** Spinogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-03-25
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-10-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** patients treated on compassionate use program
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833281, "Extension Study of Participants From SPG302-ALZ-101". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06833281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*